Categories: News

Molecular Templates to Participate in Upcoming Virtual Investor Conferences

AUSTIN, Texas, Feb. 26, 2021 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it will present and participate in 1-on-1 investor meetings at the Cowen 41st Annual Health Care Conference, the Barclays Global Healthcare Conference and the Oppenheimer 31st Annual Healthcare Conference.

Cowen 41st Annual Health Care Conference
Conference Dates: March 1-4
Presentation Date and Time: Thursday, March 4th at 11:10 AM ET
        
Barclays Global Healthcare Conference
Conference Dates: March 9-11
Presentation Date and Time: Wednesday, March 10th at 3:00 PM ET

Oppenheimer 31st Annual Healthcare Conference
Conference Dates: March 16-17
Presentation Date and Time: Wednesday, March 17th at 11:20 AM ET         

Live webcasts of these presentations will be available in the “News and Events” section of the MTEM website at www.mtem.com. Additionally, replays of the webcasts will be available on the corporate website following the conferences. 

About Molecular Templates  
Molecular Templates is a clinical-stage company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Investor Contact:
Adam Cutler
Chief Financial Officer
adam.cutler@mtem.com
862-204-4006

Source: Molecular Templates, Inc.

Staff

Recent Posts

Waystar announces term loan repricing and credit rating upgrades from Fitch, Moody’s, and S&P Global

Reduces Waystar's cost of capital and enhances its ability to allocate free cash flow towards…

10 hours ago

NUTEX HEALTH ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT

HOUSTON, June 27, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:…

10 hours ago

Chroma Medicine Announces Exclusive License Agreement with the Whitehead Institute for Novel Epigenetic Editing Technology

License provides exclusive access to innovative epigenetic editors and expands the reach of Chroma's platform…

10 hours ago

Pulmonary Fibrosis Foundation’s 2024 PFF Walk Raises Funds Toward a Cure

Nationwide Walk Series Kicks Off July 20 in Pittsburgh CHICAGO, June 27, 2024 /PRNewswire/ --…

10 hours ago

Zoi Capital Founders and Industry Veterans Announce 200 Million Dollar Fund Targeting AI Technologies with Practical Applications for Healthcare

The Venture Capital Firm Set to Expand Investments in Innovative Healthcare Companies NEW YORK, June…

10 hours ago